Commentary · 21 Feb 2026
Conference abstractPublished 21 Oct 2013
Biological effects of therapeutic siRNA against TMPRSS2-ERG fusion oncogene for the treatment of prostate cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Prostate cancer is one of the most common tumors in men worldwide and the second leading cause of death among all cancer types in western countries. Combined with surgery, hormone therapy is the first line treatment administrated for hormone-dependent prostate cancers, however when the pathology turns into a castration independent phase, the treatments become less specific. New specific molecular targets would then be highly useful to develop innovative personalized medicines. Among these targets Tomlins et al. decrypted in 2005 a chromosomal rearrangement resulting in the fusion of TMPRSS2 gene with members of the E26 Transformation-Specific (ETS) family and in particular E26 related gene (ERG). The TMPRSS2-ERG genomic fusion is found in 50% of localized and 30% of metastatic prostate cancers and this particular chromosomal rearrangement lead to more aggressive cancer phenotypes and worst cancer-specific survival rate. Because TMPRSS2-ERG fusions were found to be involved in carcinogenesis and tumor development, we conceived new possible therapeutic siRNAs specifically directed against TMPRSS2-ERG oncogene. ERG mRNA and protein levels were dramatically down-regulated after siRNA transfection in TMPRSS2-ERG positive cell line. Microarray analysis showed regulation of apoptosis related genes by TMPRSS2-ERG siRNA which was confirmed by Western blot and fluorescent kit assays and regulation of other genes involved in intracellular protein trafficking. In addition, cell viability was compromised and angiogenesis appeared to be affected. The siRNAs are now bioconjugated with lipids to obtain nanoparticles in order to evaluate their potential antitumor effects in vivo.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Giorgia Urbinati”
